As More Products Get Priority Review, User Fee Cost Gap From Standard Review Is Narrowing
US FDA’s priority review voucher fee will decrease again in FY 2022 as the cost of a priority assessment continues to trend closer to the cost of a standard assessment.
You may also be interested in...
Program growth beyond supplements will be determined after the agency gains experience with STAR program, PhRMA executive tells the Pink Sheet.
The agency reissued the user fee notice, saying fewer dollars were needed for new staff.
In part because assessment costs plummeted in FY 2019, the FY 2021 fee to redeem a priority review voucher will be 37% less than the previous year.